Exactly, Hike. There are people that would gladly take a 20% return over the course of an entire year and think it was a great financial investment. To us from here, that would be another .08 or so.
So the two questions are 1. Based on the evidence to date will this will be accepted by the FDA and 2. If the answer to 1 is "yes" than will move up over .08 between now and a few months after such an approval? Thus even the perspective a simple move to $1 from here would be huge by investment return standards, and there is plenty of reason to believe that it will go far beyond that given the urgent public health demand for the ADT's, and our position in the market with more rolling out.
The actual risk/reward profile here is laughable. We are still almost priced at "for bankruptcy" levels. There are many pharma stocks out there, not hard to find, with market caps of 1-3 billion range with drugs in P2, and either going deep into debt or having to cut deals with big pharma and give away the store. We know were so undervalued, we are actually spoiled--most here would be very disappointed if told the stock would "only" be up say, .16, or even .32 from where we were today a year from now, let alone potentially over a much shorter period.
GLTY,
Maz
News 
Market Data 
Discover 
AI
